Theragenics Signs Brachytherapy Supply and Reseller Agreement with UK-Based Accelyon
05 Juillet 2013 - 1:30PM
Business Wire
Theragenics Corporation® (NYSE: TGX), a medical device company
serving the surgical products and prostate cancer treatment
markets, today announced it has signed a Supply and Reseller
agreement with Accelyon Limited. Under the three-year agreement,
Theragenics will supply its AgX100® seeds to Accelyon who will
provide for the loading and packaging of the seeds into
prescription loaded needles, custom strands and other
configurations. Accelyon will distribute the finished products in
the European Union, Australia and New Zealand.
“This Agreement is our first major opportunity to penetrate
Europe, Australia and New Zealand with our brachytherapy seed
product,” said M. Christine Jacobs, Chairman and Chief Executive
Officer of Theragenics Corporation. “Accelyon is a new entrant into
the brachytherapy marketplace with experienced talent. The company
is managed by industry veterans possessing direct brachytherapy
experience in all these markets. We have expected our AgX100®
iodine seed to provide opportunities outside of the United States.
Accelyon provides us this access in these important brachytherapy
markets. They have international expertise and reach we do not
possess. We are thrilled to begin a new brachytherapy relationship
with Accelyon.”
“Accelyon’s people bring a wealth of experience in the European
and Australasia brachytherapy marketplaces,” said Saheed Rashid,
Managing Director of Accelyon. “We understand what is important to
customers and are committed to delivering the highest standards of
quality and reliability. Theragenics is a high quality manufacturer
and well-known brand throughout the brachytherapy world. They share
Accelyon’s commitment to this important treatment. We are excited
to begin this new relationship with Theragenics.”
About Theragenics
Theragenics Corporation (NYSE: TGX) operates two business
segments: its surgical products business and its brachytherapy seed
business. The surgical products business (www.cpmedical.com,
www.galtmedical.com, www.needletech.com) manufactures and
distributes wound closure, vascular access, and specialty needle
products. Wound closure products include sutures, needles and other
surgical products. Vascular access includes introducers, guidewires
and related products. Specialty needles include coaxial, biopsy,
spinal and disposable veress needles, access trocars,
radiofrequency devices, implanters, introducer products, and other
needle-based products. The surgical products segment serves a
number of markets and applications, including, among other areas,
interventional cardiology, interventional radiology, vascular
surgery, orthopedics, plastic surgery, dental surgery, urology,
veterinary medicine, pain management, endoscopy, and spinal
surgery. Theragenics’ brachytherapy business manufactures, custom
loads, markets and distributes “seeds” used primarily in the
minimally invasive treatment of localized prostate cancer. The
Company’s brachytherapy product line (www.theragenicsbrachy.com)
includes its palladium-103 TheraSeed® device and its iodine-125
AgX100® device. The terms "Company," "we," "us," or "our" mean
Theragenics Corporation and all entities included in our
consolidated financial statements. For additional information, call
our Investor Relations Department at (800) 998-8479 or visit
www.theragenics.com.
About Accelyon
Accelyon Limited is a new company aiming to become one of the
leading partners to hospitals and clinics worldwide in providing
brachytherapy to treat prostate cancer. Accelyon understands that
offering prostate cancer patients brachytherapy depends on
physicians having access to high quality products delivered with
expertise and reliability. Accelyon brings a new focus and
unrivalled commitment to brachytherapy – and an established,
world-class service.
This press release contains forward looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, the accuracy of which is necessarily subject to risks and
uncertainties, including, without limitation, statements regarding
expected annual revenue at full ramp up from the Accelyon
agreement. Actual results may differ materially due to a variety of
factors, including, among other things, risks and uncertainties
related to competition within the medical device industry,
development and growth of new applications within the brachytherapy
market and, more broadly, medical devices, competition from other
companies within the brachytherapy market and medical device
markets, competition from other methods of treatment, new product
development cycles (pipeline), effectiveness and execution of
marketing and sales programs, changes in product pricing, changes
in costs of materials used in production processes, changes in the
ordering patterns of our customers, continued acceptance of and
demand for our products by the markets in which we operate,
introduction and/or availability of competitive products by others,
potential changes in third-party reimbursement, including Medicare
reimbursement as administered by the Centers for Medicare and
Medicaid Services (CMS), implementation of new legislation by CMS,
physician training, third-party distribution agreements, ability to
execute on acquisition opportunities on favorable terms and
successfully integrate any acquisitions, potential changes in
applicable tax rates, legislative changes to healthcare markets and
industries, the Patient Protection and Affordable Care Act and the
Health Care and Education Reconciliation Act (including provisions
such as the medical device tax that became effective January 1,
2013), and other factors set forth from time to time in our filings
with the Securities and Exchange Commission.
All forward looking statements and cautionary statements
included in this document are made as of the date hereof based on
information available to us as of the date hereof, and we assume no
obligation to update any forward looking statement or cautionary
statement.
Theragenics (NYSE:TGX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Theragenics (NYSE:TGX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024